A5077464927- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Health and Medical Research Impacts
- Prostate Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Frailty in Older Adults
- Occupational and environmental lung diseases
- Prostate Cancer Treatment and Research
- Global Cancer Incidence and Screening
- Biomedical Ethics and Regulation
- COVID-19 and healthcare impacts
- Pharmaceutical Practices and Patient Outcomes
- Brain Metastases and Treatment
- Tuberous Sclerosis Complex Research
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Medication Adherence and Compliance
- Effects of Radiation Exposure
University of Manitoba
2014-2024
CancerCare Manitoba
2020-2024
University of British Columbia
2022
Background: COVID-19 has spread rapidly, requiring health delivery systems to undertake dramatic transformations. To evaluate these system changes, we undertook one of the first Canadian reviews and cancer centre evaluation pandemic modifications. Methods: Questionnaires were distributed Association Provincial Cancer Agencies (CAPCA) members in order assess changes services patient management. Documentation relating from CAPCA electronic space was accessed, all publicly available...
Constitutional mismatch repair deficiency (CMMRD) is a rare autosomal recessive hereditary cancer syndrome due to biallelic germline mutation involving one of the four DNA genes. Here we present case young female with CMMRD, homozygous for c.2002A>G in PMS2 gene. She developed an early stage adenocarcinoma colon at age 14. Surveillance MRI brain 18 resulted detection asymptomatic cancer. On resection, this was diagnosed as anaplastic astrocytoma. Due emerging literature suggesting benefit...
Platinum-based chemotherapy was compared to single-agent pembrolizumab in advanced non-small cell lung cancer (NSCLC) with PDL1 > 50% KEYNOTE-024. In this trial, it found that patients who received had improved progression-free survival addition overall (OS). Based on KEYNOTE-024, only 53% of treated originally second-line anticancer systemic therapy an OS 26.3 months. these results, the objective study characterize real-world NSCLC after pembrolizumab.This a retrospective cohort considering...
Extensive-stage small-cell lung cancer (ES-SCLC) is an incurable with poor prognosis in which characteristics predictive of long-term survival are debated. The utility agents such as immune checkpoint inhibitors highlights the importance identifying key and treatment strategies that contribute to could help guide therapeutic decisions.
Small cell lung cancer (SCLC) is a rapidly progressing aggressive malignancy. Durvalumab in CASPIAN and atezolizumab IMPower133 were found to improve overall survival (OS) for extensive-stage SCLC. Here we evaluate the proportion of real-world ES SCLC patients who may be eligible first-line immune checkpoint inhibitor (ICI) with platinum doublet.A retrospective cohort analysis was conducted referred between 2015 2017 British Columbia, Canada. Patient demographics, staging, treatment, data...
Immunotherapy is less effective in non-small cell lung cancer (NSCLC) with driver mutations epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) and some may extrapolate this trend to other mutations. Up 4% of NSCLC cases contain a BRAF mutation. Most are V600E, little known about the impact treatment rare G469A We present case patient found have mutated NSCLC. She was diagnosed Stage IIIB treated concurrent chemotherapy radiation. Post-treatment imaging demonstrated...
The US Food and Drug Administration (FDA) introduced an Accelerated Approval (AA) pathway to expedite patient access new drugs. AA accepts less rigorous trial designs, including single-arm studies (SAS), owing perceived lack of feasibility timely randomized controlled trials (RCTs).We designed hypothetical RCTs with endpoints overall response rate (ORR), progression-free survival (PFS), (OS) for FDA approvals based on SAS solid tumors during 2010-2019. Existing standards care served as...
A fixed dose of 200 mg pembrolizumab every 3 weeks (Q3W) is the standard care for patients with stage IV non-small cell lung cancer (NSCLC) and PDL1 ≥50%. In April 2020, based on pharmacokinetic modeling without formal comparative studies, FDA approved 400 6 (Q6W). Pharmacokinetic studies also suggested comparable target engagement weight-based flat dosing respective schedules. The objective this study was to determine if overall survival (OS) differs Q3W vs. Q6W schedule pembrolizumab.BC...
Renal angiomyolipoma (AML) is predominantly a non-aggressive benign tumour. Cases of more aggressive AMLs are present in the literature. We 2 cases AML behaviour. The first case an with vascular extension young female and second found regional lymph nodes left renal cell carcinoma.
Objectives: Advanced pancreatic cancer (APC) disproportionately impacts older adults. Randomized trials demonstrate improved overall survival (OS) with combination chemotherapy including 5-fluorouracil, irinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) or nab -paclitaxel gemcitabine compared alone, but increased toxicity. Older adults are at risk of side effects from chemotherapy. The aim this study was to assess the efficacy toxicity in APC. Methods: Patients diagnosed APC 2011 2016 were...
Abscopal effect is a rare phenomenon in which treatment benefit from radiotherapy (RT) seen outside the target field due to activation of immune system inducing an anti-tumor effect. This has been reported cancer patients receiving checkpoint inhibitors (ICI). Here we report case presumed abscopal malignant mesothelioma. The patient received second-line single-agent pembrolizumab however had disease progression after four cycles leading palliative RT (20 Gray) right mainstem bronchus....
Osimertinib is a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor currently used as first-line systemic therapy for advanced EGFR mutant non-small cell lung cancer. generally very well tolerated with only 1% risk of grade 3-4 skin toxicity. Here we present case 68-year-old Asian male exon 19 deletion After initiation osimertinib 80 mg daily, he had rapid worsening his pre-existing scaly psoriatic plaques desquamation. Treatment was withheld...
Although therapy for limited-stage small-cell lung cancer (LS-SCLC) is administered with curative intent, most patients relapse and eventually die of recurrent disease. Chemotherapy (CT) concurrent radiotherapy (RT) remains the standard care LS-SCLC; however, this could evolve in near future. Therefore, understanding current prognostic factors associated survival essential.This real-world analysis examines long-term LS-SCLC treated CT Manitoba, Canada.A retrospective cohort study was...
e18704 Background: Rapid advances in precision oncology challenge timely and sustainable reimbursement decisions. Life-cycle health technology assessment (LC-HTA) can enable conditional patient access to promising innovations alongside evidence development. Our objective was create a life-cycle evaluative framework, called PRecision Evidence Development Cancer Treatment (PREDiCT). Methods: Through an iterative, system stakeholder-informed approach, we designed our LC-HTA framework. Elements...
High-intensity focused ultrasound (HIFU) is a treatment option for low- and intermediate-risk prostate cancer more recently has been used as salvage therapy after failed radiation therapy. We present case of local recurrence with biochemical failure radical prostatectomy external beam HIFU without at 20 months.
Background: In the ATLANTIS study, second-line lurbinectedin/doxorubicin did not improve overall survival (OS), however patients with a chemotherapy-free interval (CTFI) of ≥180 days had an improved progression free (PFS). The objective this retrospective study was to identify proportion real-world small cell lung cancer (SCLC) who are suitable for lurbinectedin-based therapy based on these criteria. Methods: A all SCLC referred BC Cancer between 2012 and 2017 conducted. Patient...
9120 Background: Over 15 years, diagnostic and therapeutic algorithms for Stage IV non-small cell lung cancer (NSCLC) have dramatically progressed. While clinical trials demonstrate overall survival (OS) advantages, population level impact remains uncertain. Here we evaluate real world, population-based outcomes NSCLC to assess of changing therapies on referral, treatment patterns OS, which may help explain ongoing stigma/nihilism. Methods: A retrospective cohort analysis was completed de...